ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more
ISU Abxis Co. Ltd (086890) - Total Liabilities
Latest total liabilities as of September 2025: ₩45.29 Billion KRW
Based on the latest financial reports, ISU Abxis Co. Ltd (086890) has total liabilities worth ₩45.29 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ISU Abxis Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how ISU Abxis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ISU Abxis Co. Ltd Competitors by Total Liabilities
The table below lists competitors of ISU Abxis Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anfield Energy Inc.
NASDAQ:AEC
|
USA | $36.89 Million |
|
Ador Welding Limited
NSE:ADORWELD
|
India | ₹1.87 Billion |
|
JUKCF
PINK:JUKCF
|
USA | $97.26 Billion |
|
Sao Ta Foods JSC
VN:FMC
|
Vietnam | ₫2.22 Trillion |
|
Bancorp. of Southern Indiana
PINK:BCSO
|
USA | $908.91 Million |
|
Hikal Limited
NSE:HIKAL
|
India | ₹11.55 Billion |
|
HYUNDAI FEED Inc
KQ:016790
|
Korea | ₩28.17 Billion |
|
Intai Technology
TWO:4163
|
Taiwan | NT$2.12 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down ISU Abxis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ISU Abxis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ISU Abxis Co. Ltd (2014–2024)
The table below shows the annual total liabilities of ISU Abxis Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩59.37 Billion | -54.17% |
| 2023-12-31 | ₩129.55 Billion | +77.81% |
| 2022-12-31 | ₩72.86 Billion | -7.94% |
| 2021-12-31 | ₩79.14 Billion | +102.03% |
| 2020-12-31 | ₩39.17 Billion | +4.24% |
| 2019-12-31 | ₩37.58 Billion | +271.87% |
| 2018-12-31 | ₩10.11 Billion | -35.69% |
| 2017-12-31 | ₩15.71 Billion | +10.23% |
| 2016-12-31 | ₩14.26 Billion | -39.11% |
| 2015-12-31 | ₩23.41 Billion | -25.87% |
| 2014-12-31 | ₩31.59 Billion | -- |